Literature DB >> 31737965

The evolution of addiction treatment and harm reduction programs in Iran: a chaotic response or a synergistic diversity?

Hamed Ekhtiari1,2, Alireza Noroozi1,3, Ali Farhoudian4,5, Seyed Ramin Radfar4,6, Ahmad Hajebi7, Saeed Sefatian8, Mehran Zare-Bidoky1,9, Emran Mohammad Razaghi5, Azarakhsh Mokri1,5, Afarin Rahimi-Movaghar1, Richard Rawson6,10.   

Abstract

BACKGROUNDS AND AIMS: Iran has 2.1 and 1.8% of its 15-64-year-old population living with illicit substance and opioid use disorders, respectively. To address these problems, Iran has been developing a large and multi-modality addiction treatment system, spanning the time before and after the Islamic Revolution.
METHODS: Iran's current drug treatment scene is a combination of services, ranging from medical/harm reduction services to punitive/criminal justice programs. Included in this array of services are drop-in centers providing low-threshold harm reduction services, such as distribution of sterile needles and syringes; opioid maintenance treatment clinics providing methadone, buprenorphine and opium tincture; and abstinence-based residential centers. We will review the evolution of this system in four phases.
RESULTS: In 1980, Iran's revolutionary government shut down all voluntary treatment programs and replaced them with residential correctional programs. The first shift in the addiction treatment policies came 15 years later after facing the negative consequences. Addiction is viewed as a disease, and new voluntary treatment centers offering non-agonist medications and psychosocial services were established. With an increased number of people who inject drugs and HIV/AIDS epidemics, in the second shift an extensive move towards harm reduction strategies and opioid-maintenance programs has been implemented to reduce HIV-related high-risk behavior. The emergence of a methamphetamine use crisis creating an increased number of socially marginalized addicted people resulted in public and political demands for stricter policies and ended in the third shift starting in 2010, with extended compulsory court-based residential programs. Currently, there is a new shift towards reducing the severity of criminal penalties for drug use/sales and promoting proposals for opium legalization.
CONCLUSION: Iran's evolutionary experience in developing a large addiction treatment program in a complex combination of medical/harm reduction and punitive/criminal justice addiction treatment can be examined in its political, clinical and pragmatic context.
© 2019 Society for the Study of Addiction.

Entities:  

Keywords:  Addiction treatment; HIV/AIDS; Iran; harm reduction; methadone; opioid; policy

Mesh:

Year:  2019        PMID: 31737965     DOI: 10.1111/add.14905

Source DB:  PubMed          Journal:  Addiction        ISSN: 0965-2140            Impact factor:   6.526


  6 in total

1.  Ontological journeys: The lifeworld of opium across the Afghan-Iranian border in/out of the pharmacy.

Authors:  Maziyar Ghiabi
Journal:  Int J Drug Policy       Date:  2021-01-21

2.  HIV Prevalence and Related Behaviors Among People Who Inject Drugs in Iran from 2010 to 2020.

Authors:  Mohammad Karamouzian; Hamid Sharifi; Mehrdad Khezri; Mostafa Shokoohi; Ali Mirzazadeh; Fatemeh Tavakoli; Nima Ghalekhani; Ghazal Mousavian; Soheil Mehmandoost; Parvin Afsar Kazerooni; Ali Akbar Haghdoost
Journal:  AIDS Behav       Date:  2022-02-23

3.  HIV prevalence and continuum of care among incarcerated people in Iran from 2010 to 2017.

Authors:  Armita Shahesmaeili; Mohammad Karamouzian; Fatemeh Tavakoli; Mostafa Shokoohi; Ali Mirzazadeh; Samira Hosseini-Hooshyar; Saber Amirzadeh Googhari; Nima Ghalekhani; Razieh Khajehkazemi; Zahra Abdolahinia; Noushin Fahimfar; AliAkbar Haghdoost; Hamid Sharifi
Journal:  Harm Reduct J       Date:  2022-08-20

4.  Opioid agonist therapy uptake among people who inject drugs: the findings of two consecutive bio-behavioral surveillance surveys in Iran.

Authors:  Mehran Nakhaeizadeh; Zahra Abdolahinia; Hamid Sharifi; Ali Mirzazadeh; Ali Akbar Haghdoost; Mostafa Shokoohi; Stefan Baral; Mohammad Karamouzian; Armita Shahesmaeili
Journal:  Harm Reduct J       Date:  2020-07-22

5.  Coordination, cooperation, and creativity within harm reduction networks in Iran: COVID-19 prevention and control among people who use drugs.

Authors:  Maryam Alavi; Amir Moghanibashi-Mansourieh; Seyed Ramin Radfar; Sepideh Alizadeh; Fatemeh Bahramabadian; Sara Esmizade; Gregory J Dore; Farid Barati Sedeh; Abbas Deilamizade
Journal:  Int J Drug Policy       Date:  2020-08-17

Review 6.  Hepatitis B virus infection among people who use drugs in Iran: a systematic review, meta-analysis, and trend analysis.

Authors:  Yasna Rostam-Abadi; Hossein Rafiemanesh; Jaleh Gholami; Behrang Shadloo; Masoumeh Amin-Esmaeili; Afarin Rahimi-Movaghar
Journal:  Harm Reduct J       Date:  2020-10-21
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.